Non-small cell lung cancer stage I – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:01:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-small cell lung cancer stage I – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features https://clinicaltrials.eu/trial/study-on-datopotamab-deruxtecan-and-rilvegostomig-for-stage-i-non-small-cell-lung-cancer-patients-with-ctdna-positive-or-high-risk-features/ Wed, 29 Apr 2026 15:04:11 +0000 https://clinicaltrials.eu/trial/study-on-datopotamab-deruxtecan-and-rilvegostomig-for-stage-i-non-small-cell-lung-cancer-patients-with-ctdna-positive-or-high-risk-features/ This clinical trial is focused on studying a type of lung cancer known as Stage I adenocarcinoma non-small cell lung cancer (NSCLC). This study is particularly interested in patients who have a positive result for circulating tumor DNA (ctDNA) or have certain high-risk features after their tumor has been completely removed through surgery. The trial will explore the effectiveness and safety of a new treatment option using a combination of two medications: Datopotamab deruxtecan and Rilvegostomig, which is also known by its code name AZD2936. These medications are given as a solution through a vein, a method known as intravenous infusion.

The purpose of the study is to see if the combination of Datopotamab deruxtecan and Rilvegostomig works better than the standard treatments currently available. Participants in the study will be randomly assigned to receive either the new combination treatment, Rilvegostomig alone, or the standard care, which may include medications like Pemetrexed, Vinorelbine, Carboplatin, Cisplatin, Etoposide, Infliximab, or Mycophenolate mofetil. Some participants may receive a placebo. The study will monitor participants over time to assess how well the treatments work and to check for any side effects.

Throughout the study, researchers will collect information on how long participants remain free of cancer, known as disease-free survival, and overall survival, which is the length of time participants live after starting the study. They will also look at how the treatments affect participants’ physical function and quality of life. Additionally, the study will measure the levels of the medications in the blood and check for any immune reactions to the treatments. The trial aims to provide valuable insights into improving treatment options for patients with this type of lung cancer.

]]> Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-chemotherapy-with-paclitaxel-cisplatin-and-carboplatin-for-patients-with-resected-stage-i-or-iia-non-squamous-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:30:38 +0000 https://clinicaltrials.eu/trial/study-on-chemotherapy-with-paclitaxel-cisplatin-and-carboplatin-for-patients-with-resected-stage-i-or-iia-non-squamous-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-squamous non-small cell lung cancer (NSCLC) that has been completely removed through surgery. The study involves patients with early stages of this cancer, specifically stage I or IIA, who are identified as having a high or intermediate risk of cancer returning. The purpose of the study is to explore the benefits of using additional treatment, called adjuvant chemotherapy, after surgery to help prevent the cancer from coming back. This treatment involves using a combination of medications, including Paclitaxel, Cisplatin, Carboplatin, Vinorelbine Tartrate, Docetaxel, and Pemetrexed, which are administered through an intravenous infusion, meaning they are given directly into a vein.

The study is designed to compare two groups of patients: those who receive the chemotherapy treatment and those who do not, to see if the treatment helps in extending the time patients remain free from cancer. The chemotherapy treatment is given in cycles, with each cycle lasting a few weeks, and the total treatment period can last up to 16 weeks. The study aims to personalize patient care by using a special test called the 14-Gene Prognostic Assay, which helps determine the risk level of cancer returning based on the genetic makeup of the tumor.

Participants in the study will be monitored over time to track their health and any signs of cancer returning. The study will help researchers understand if using chemotherapy after surgery can improve outcomes for patients with high or intermediate risk of cancer recurrence. This information could lead to better treatment strategies for patients with early-stage non-squamous NSCLC in the future.

]]> Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-osimertinib-for-patients-with-stage-ib-iiia-non-small-cell-lung-cancer-after-tumor-removal/ Wed, 29 Apr 2026 14:28:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-osimertinib-for-patients-with-stage-ib-iiia-non-small-cell-lung-cancer-after-tumor-removal/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) in its early stages, specifically stages IB to IIIA. The study is particularly interested in patients whose cancer has specific changes in the epidermal growth factor receptor (EGFR) gene, which are known to respond to certain treatments. The treatment being tested is a medication called osimertinib, also known by its code name AZD9291. This medication is compared to a placebo to evaluate its effectiveness and safety in preventing the return of cancer after the tumor has been completely removed through surgery, with or without additional chemotherapy.

The purpose of the study is to determine how well osimertinib works in keeping the cancer from coming back, which is referred to as disease-free survival. Participants in the study will be randomly assigned to receive either osimertinib or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, a method known as double-blind. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will be monitored for several years to assess the long-term effects of the treatment. This includes regular check-ups and tests to track their health and any changes in their condition. The study will also look at overall survival rates and the quality of life of the participants, using questionnaires and other assessments. The safety of the treatment will be closely watched by checking for any side effects or health changes during the study period.

]]> Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-stereotactic-body-radiotherapy-with-or-without-pembrolizumab-for-patients-with-unresected-stage-i-or-ii-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:24:55 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-stereotactic-body-radiotherapy-with-or-without-pembrolizumab-for-patients-with-unresected-stage-i-or-ii-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC), specifically in its early stages, Stage I or II, where the cancer cannot be removed by surgery. The study is investigating the effects of a treatment called pembrolizumab, also known by its code name MK-3475, which is a medication given through an intravenous infusion. Pembrolizumab is being tested in combination with a type of precise radiation therapy called Stereotactic Body Radiotherapy (SBRT). The trial will compare the outcomes of patients receiving SBRT with pembrolizumab to those receiving SBRT with a placebo, which is a substance with no active medication.

The purpose of this study is to evaluate the safety and effectiveness of the treatment combinations in patients with unresectable NSCLC. Participants in the study will be randomly assigned to receive either the combination of SBRT and pembrolizumab or SBRT and a placebo. The study will monitor participants over a period to assess how long they remain free from events such as cancer progression or recurrence, which is referred to as Event-Free Survival (EFS). Additionally, the study will look at overall survival rates and other health outcomes related to quality of life and side effects.

Throughout the study, participants will undergo regular health assessments to track their response to the treatment and any side effects they may experience. The trial aims to provide valuable information on whether adding pembrolizumab to SBRT can improve outcomes for patients with early-stage NSCLC who cannot undergo surgery. The study is expected to continue until 2026, with ongoing evaluations to ensure the safety and well-being of all participants.

]]>